{"schema_version":"secwatch.filing_event.v1","accession":"0000320017-25-000037","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2025-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.932144+00:00","generated_at":"2026-05-19T09:28:21.110233+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Lisata Therapeutics raises CEO salary to $717,229, CMO salary to $599,342 in amended employment agreements","bullets":["CEO David Mazzo base salary increased to $717,229 from $633,032; $12,000 non-accountable expense allowance removed.","CMO Kristen Buck base salary increased to $599,342 from $550,000.","Amended severance terms for CEO, CMO, CAO Nisco, and GC Imam; includes COBRA reimbursement changes and Section 409A clarifications.","Change in Control definition amended to include shareholder-approved complete liquidation, subject to 409A requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0000320017-25-000037","json":"https://secwatch.observer/filing/0000320017-25-000037.json","markdown":"https://secwatch.observer/filing/0000320017-25-000037.md","text":"https://secwatch.observer/filing/0000320017-25-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000032001725000037/0000320017-25-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000032001725000037/clbs-20250610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T09:28:21.110233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}